SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
BALTIMORE, April 05, 2016 -- WellDoc, a digital health technology leader, announced today that healthcare industry veteran Nick Harsh has joined the company as Vice President, Market Access. In this new role, Mr. Harsh will be responsible for leading WellDoc’s payer strategy, relationships and execution.
“WellDoc is utilizing 21st century technology to partner patients and their caregivers with medical providers to deliver better healthcare outcomes,” said Mr. Harsh. “I’m excited about my new role with WellDoc, and the impact we can make on the management of type 2 diabetes and other chronic diseases.”
Over the last 15 years, Mr. Harsh been a part of the management team for the AstraZeneca organization, launching and supporting several AstraZeneca and MedImmune well-recognized brands, including Nexium®, Crestor® and FluMist ®. Most recently, he led the commercial strategy, pricing, operations, and channel distribution services for MedImmune’s specialty biologics. Mr. Harsh has spent more than 30 years in the pharmaceutical, medical device and biotech fields—in senior commercial roles leading the market access initiatives.
“Nick is a great addition to our growing WellDoc leadership team,” said Kevin McRaith, Chief Executive Officer at WellDoc. “The breadth and depth of his managed market knowledge and experience with product commercialization will allow WellDoc to expand the market presence of BlueStar® and future digital health products.”
About WellDoc®
WellDoc is a digital health technology company that develops mobile solutions to drive behavioral and clinical change in chronic disease. WellDoc’s goal is to improve patient self-management and help physicians overcome gaps in the delivery system to improve clinical outcomes and decrease cost. WellDoc has commercialized BlueStar®, a digital therapeutic, for adults with type 2 diabetes. This therapeutic is designed to fill the support gap between patients and providers during the 8700 hours that individuals live their lives outside the healthcare system each year. WellDoc has a proven track record of contributing published, peer-reviewed clinical evidence since 2008 and in June 2015 presented real-world patient engagement and clinical outcomes at the American Diabetes Association’s (ADA) 75th Scientific Session. BlueStar® is recognized by the ADA on its website as the first and only in the new class of diabetes treatment known as Mobile Prescription Therapy. In a recently published Forbes blog, WellDoc was named among one of five healthcare tech companies to watch in 2016. For more information, visit www.WellDoc.com and www.BlueStarDiabetes.com.
Media contact: Juliette Bogus PressComm PR Tel: +410-980-5687 Email: [email protected]
